Conivaptan: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Conivaptan": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
No edit summary |
||
| Line 1: | Line 1: | ||
{{drugbox | | {{drugbox | | ||
| IUPAC_name = ''N-(4-(4,5-dihydro-2-methylimidazo<nowiki>[4,5-d][1]</nowiki>benzazepin-<BR>6(1H)-yl)carbonyl)phenyl)-<BR>(1,1'-biphenyl)-2-carboxamide'' | | IUPAC_name = ''N-(4-(4,5-dihydro-2-methylimidazo<nowiki>[4,5-d][1]</nowiki>benzazepin-<BR>6(1H)-yl)carbonyl)phenyl)-<BR>(1,1'-biphenyl)-2-carboxamide'' | ||
| Line 27: | Line 25: | ||
}} | }} | ||
{{CMG}} | |||
==Overview== | |||
'''Conivaptan''' ('''vaprisol'''®, YM 087) is a non-peptide inhibitor of [[antidiuretic hormone]] (vasopressin). It was approved in 2004 for [[hyponatremia]] (low blood [[sodium]] levels) caused by [[syndrome of inappropriate antidiuretic hormone]] (SIADH), and there is some evidence it may be effective in [[heart failure]]. It is marketed by [[Astellas Pharma|Astellas Pharma Inc]]. | '''Conivaptan''' ('''vaprisol'''®, YM 087) is a non-peptide inhibitor of [[antidiuretic hormone]] (vasopressin). It was approved in 2004 for [[hyponatremia]] (low blood [[sodium]] levels) caused by [[syndrome of inappropriate antidiuretic hormone]] (SIADH), and there is some evidence it may be effective in [[heart failure]]. It is marketed by [[Astellas Pharma|Astellas Pharma Inc]]. | ||
==Mechanism of Action== | |||
Conivaptan inhibits both isotypes of the [[vasopressin receptor]] ([[Arginine vasopressin receptor 1A|V1a]] and [[Arginine vasopressin receptor 2|V2]]). Effectively, it causes [[iatrogenic]] nephrogenic [[diabetes insipidus]]. | Conivaptan inhibits both isotypes of the [[vasopressin receptor]] ([[Arginine vasopressin receptor 1A|V1a]] and [[Arginine vasopressin receptor 2|V2]]). Effectively, it causes [[iatrogenic]] nephrogenic [[diabetes insipidus]]. | ||
==See also== | ==See also== | ||
* [[Tolvaptan]] | * [[Tolvaptan]] | ||
==References== | |||
{{Reflist|2}} | |||
[[Category:Hormonal agents]] | [[Category:Hormonal agents]] | ||
[[Category:Diuretics]] | [[Category:Diuretics]] | ||
[[Category:Drugs]] | |||
{{ | {{WH}} | ||
{{WS}} | |||
Revision as of 11:10, 16 October 2011
| File:Conivaptan structure.svg | |
| Clinical data | |
|---|---|
| Routes of administration | iv |
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C32H26N4O2 |
| Molar mass | 498.583 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Conivaptan (vaprisol®, YM 087) is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH), and there is some evidence it may be effective in heart failure. It is marketed by Astellas Pharma Inc.
Mechanism of Action
Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). Effectively, it causes iatrogenic nephrogenic diabetes insipidus.
See also
References
Categories:
- Pages with script errors
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Hormonal agents
- Diuretics
- Drugs